Chimeric antigen receptor T cell (CART) products targeting CD19 have been approved for the treatment of patients with relapsed and/or refractory (r/r) B cell malignancies [1–4], including patients with acute lymphoblastic leukemia (ALL) [2, 3]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.